2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2835

Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Abstract Number: 2836

Microparticles of Endothelial Origin in Women with Systemic LUPUS Erythematosus UNDER Treatment
Abstract Number: 2837

Importance of Mixed Speckled/ Homogeneous DFS70 ANA Patterns
Abstract Number: 2838

Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort
Abstract Number: 2839

Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 2840

Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
Abstract Number: 2841

Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Abstract Number: 2842

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
Abstract Number: 2843

Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases
Abstract Number: 2844

Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus
Abstract Number: 2845

Antineutrophil Cytoplasmic Antibodies in Systemic Lupus Erythematosus: Incidence, Outcome and Prognosis
Abstract Number: 2846

Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility
Abstract Number: 2847

Antibodies to Double Stranded DNA: Combined Standard ELISA and High-Salt ELISA Assays for the Detection of SLE Disease Activity
Abstract Number: 2848

Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Abstract Number: 2849

Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].